# Study of the Safety of BEMA™ Fentanyl Use for Breakthrough Pain in Cancer Subjects on Chronic Opioid Therapy

> **NCT00293020** · PHASE3 · COMPLETED · sponsor: **BioDelivery Sciences International** · enrollment: 244 (actual)

## Conditions studied

- Pain
- Cancer

## Interventions

- **DRUG:** BEMA Fentanyl

## Key facts

- **NCT ID:** NCT00293020
- **Lead sponsor:** BioDelivery Sciences International
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-02
- **Primary completion:** 2008-06
- **Final completion:** 2008-06
- **Target enrollment:** 244 (ACTUAL)
- **Last updated:** 2012-10-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00293020

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00293020, "Study of the Safety of BEMA™ Fentanyl Use for Breakthrough Pain in Cancer Subjects on Chronic Opioid Therapy". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT00293020. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*